Anabolic Bone Window With Weekly Teriparatide Therapy in Postmenopausal Osteoporosis: A Pilot Study

Gopalaswamy, Vinaya; Dhibar, Deba Prasad; Gupta, Vipin; Arya, Ashutosh Kumar; Khandelwal, Niranjan; Bhansali, Anil; Garg, Sudhir Kumar; Agarwal, Naveen; Rao, Sudhaker D; Bhadada, Sanjay Kumar

doi:10.4158/ep161394.or

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AUC 0-0.17 (pg•d/ml) increased significantly in rhPTH 1-34 PLGA MPs compared to free rhPTH 1-34 (p=0.004). MRT of rhPTH 1-34 in PLGA MPs was 3.13±0.66 d, suggesting that rhPTH 1-34 PLGA MPs can be applied as a subcutaneous injection once a week [34] .…”

Section: Resultsmentioning

confidence: 92%

Poly(lactic-co-glycolic acid) Microspheres Containing a Recombinant Parathyroid Hormone (1-34) for Sustained Release in a Rat Model

Baskaran¹,

Lee²,

Kang³

et al. 2018

Indian J Pharm Sci

View full text Add to dashboard Cite

Osteoporosis is a progressive metabolic bone disease, which decreases the bone mass and deteriorates the microstructure of the bone tissue, increasing the vulnerability of the bone to risk of fracture [1]. Certainly, various treatments have studied for osteoporosis to improve bone density include oestrogen hormone replacement therapy, calcitonin, and bisphosphonate [2]. A recombinant parathyroid hormone (rhPTH 1-34) is the last drug of choice for the treatment of osteoporosis for patients for whom all other drug regimens have failed [3]. It has advantages of activating osteoblasts as an anabolic agent and inhibiting osteoclasts simultaneously [4]. However, rhPTH 1-34 exhibited rapid elimination with a short half-life after subcutaneous injection in the body and requires daily injections in clinical practice [5]. Thus, a new strategy to prolong the therapeutic effect of rhPTH 1-34 is required in patients to avoid repeated injections [6]. A sustained release

show abstract

Section: Resultsmentioning

confidence: 92%

Poly(lactic-co-glycolic acid) Microspheres Containing a Recombinant Parathyroid Hormone (1-34) for Sustained Release in a Rat Model

Baskaran¹,

Lee²,

Kang³

et al. 2018

Indian J Pharm Sci

View full text Add to dashboard Cite

show abstract

“…These ultimately might result in enhanced bone strength. 31 McClung et al demonstrated that TPTD had a larger anabolic window than alendronate and thus had a stronger effect on BMD. Another randomised controlled trial showed that the augmentation in bone formation markers including P1NP at 3 months could predict the improvement in BMD at 1 year.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Daily Teriparatide versus One-Time Annually Zoledronic Acid Administration After Transforaminal Lumbar Interbody Fusion in Osteoporotic Patients

Wang¹,

Chen²,

Chen³

et al. 2021

CIA

View full text Add to dashboard Cite

The research aimed to compare the therapeutic effect of teriparatide (TPTD) and zoledronic acid (ZOL) therapy on bone formation and spinal fusion in patients with osteoporosis (OP) who underwent transforaminal lumbar interbody fusion (TLIF). Methods: On the basis of different anti-OP treatment options, the TPTD group was treated daily with TPTD (20 μg. ih. qd) for at least 6 months, while the ZOL group was treated with a single dose of ZOL (5 mg. ivgtt. st) postoperatively. The visual analogue scale (VAS), Oswestry Disability Index (ODI), bone mineral density (BMD), and concentration of bone turnover markers before, 6, and 12 months after surgery were evaluated. X-ray and threedimensional computed tomography scans were performed at 6 and 12 months postoperatively to assess interbody fusion. Results: The number of patients in the TPTD and ZOL groups was 29 and 38 patients, respectively. The VAS and ODI scores in both groups were significantly reduced at 6 and 12 months after TLIF. Compared with that of baseline, the lumbar spine BMD of TPTD patients increased significantly from 0.716±0.137 g/cm 2 to 0.745±0.124 g/cm 2 and 0.795±0.123 g/cm 2 at 6 and 12 months, respectively, and was significantly higher than that of the ZOL group at 12 months (0.720±0.128 g/cm 2 ). The bone formation marker, P1NP, in the TPTD group increased significantly (145.48±66.64 ng/mL and 119.55±88.27 ng/mL) compared with baseline (44.67 ±25.15 ng/mL) and in the ZOL group (28.82±19.76 ng/mL and 29.94±20.67 ng/mL) at 6 and 12 months, respectively. The fusion rates in the TPTD and ZOL groups were 57% and 45% at 6 months, without statistical significance. However, TPTD had a more statistically significant positive influence on fusion rate than ZOL at 12 months (86% vs 70%). Conclusion: TPTD was more efficient than ZOL in bone formation and spinal fusion in OP patients who underwent TLIF.

show abstract

A novel oral hPTH(1-34) unveils the promise of modeling-based anabolism with no increase in bone remodeling

Brown

2024

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Anabolic Bone Window With Weekly Teriparatide Therapy in Postmenopausal Osteoporosis: A Pilot Study

Cited by 4 publications

References 7 publications

Poly(lactic-co-glycolic acid) Microspheres Containing a Recombinant Parathyroid Hormone (1-34) for Sustained Release in a Rat Model

Poly(lactic-co-glycolic acid) Microspheres Containing a Recombinant Parathyroid Hormone (1-34) for Sustained Release in a Rat Model

The Effect of Daily Teriparatide versus One-Time Annually Zoledronic Acid Administration After Transforaminal Lumbar Interbody Fusion in Osteoporotic Patients

A novel oral hPTH(1-34) unveils the promise of modeling-based anabolism with no increase in bone remodeling

Contact Info

Product

Resources

About